Dermot Mark Durcan, Director at Cencora, Inc. (COR), bought 4,000 shares at $274.19 ($1.1M) on 2026-06-18, disclosed to the SEC on 2026-06-22.
Director Dermot Mark Durcan purchased 4,000 shares for $1.1M, marking the largest insider purchase in the company's history. This significant bet suggests insiders see value in the stock despite its recent underperformance.
COR is trading down 16.93% over the last 90 days and is currently 27.98% below its 52-week high of $377.54.
Catalysts include the launch of the Enhanced Nucleus Solution on June 18, the upcoming CFO transition to Eva C. Boratto in June 2026, and the Kite Pharma distribution partnership announced on June 10.
The stock faces a short interest risk of 3.22% and has underperformed year-to-date with shares down 18%.
Something here stands out, but not much.
| Filing → |
| ABC | BUY | 2020-03-23 | $201K | — | Filing → |
| ABC | BUY | 2020-03-16 | $202K | — | Filing → |
| MU | SELL | 2016-11-09 | $24K | — | Filing → |